Innovative Research Company Welcomes Congressman John Dingell to Its World Headquarters in Ann Arbor, Michigan
(firmenpresse) - ANN ARBOR, MI -- (Marketwire) -- 01/13/12 -- Today Therapeutic Systems Research Laboratories (TSRL), Inc. welcomed United States Congressman John Dingell to its headquarters to share their work to significantly improve current anti-influenza and antiviral drugs available on the market. In his remarks to the Congressman, John Hilfinger, President of TSRL, shared how TSRL's ability to engineer unique drug molecules promises to enhance the performance of a host of drugs. "It's amazing how many drugs don't reach their full market potential because they were designed for maximum effect and not for how well they reach their site of action," said Hilfinger. "TSRL essentially constructs drugs of the right shape and size, which then allows the drugs to be given as a tablet and the body changes them back to original drug to do their work of defeating the 'bad stuff.'" Chief on TSRL's list of targets is influenza, the cause of roughly 30,000 deaths in the U.S., and more than one million ambulatory care visits in the U.S. per year at an estimated cost of $7 billion in lost productivity due to missed days of work.
While TSRL's products could significantly improve the way we fight viruses and the common flu, the company described the uphill battle that every pioneering drug company faces when getting a product off the ground. "The biggest challenge is to secure funding beyond the early research stage," said Elke Lipka, Vice President of Business Development. "Before you can attract a large pharmaceutical firm to license your drug for full development and marketing, you have to show that it works in clinical testing." The typical development cycle for a new drug can last five or more years and require several hundred million dollars in funding. "That's where government resources and champions such as Congressman Dingell play such a vital role in helping a company like ours," explained Gordon Amidon, Chairman of TSRL, Inc. "By helping us overcome the hurdles of working with many groups within the federal government, TRSL will be better positioned to access the funding necessary to getting our solutions to clinical proof-of-concept."
A large percentage of funding for drug discovery comes from the federal government, primarily through the National Institutes of Health (NIH). Federal grants from NIH are known to be extremely competitive, as companies vie for a limited number of opportunities. Furthermore, NIH funding in support of initial clinical studies is even harder to come by. Despite the economic downturn, supporters in Congress such as Dingell have pushed for the provision of stable funding for NIH to enable the fundamental research that will lead to the next big breakthrough and to foster translational research to get promising drugs to the clinic. "We think we're on to something big," Hilfinger said. "It takes a lot of work, but we feel it will be worth it in the end."
When asked about the visit, Congressman Dingell, a strong proponent of Michigan research companies said: "Yesterday I had the opportunity to visit an innovative drug development company, TSRL, located in Ann Arbor, MI. This company has made great strides to develop drug therapies that will improve the way we treat influenza." He continued, "TSRL is a strong example of where a federal investment can help kickstart the development of promising new treatments and technologies here at home that can compete with our neighbors abroad. I urge my colleagues in Congress to continue supporting robust funding for NIH, to foster research and drug development, and the FDA so they can continue to approve and ensure the safety and effectiveness of next generation pharmaceuticals."
: Therapeutics Systems Research Laboratories (TSRL), Inc. is a privately owned oral drug delivery specialty firm located in Ann Arbor, Michigan. Combining customized problem-solving strategies with individually tailored delivery solutions, TSRL helps clients develop valuable oral therapeutic strategies. For more information about TSRL visit .
Image Available:
Elke Lipka
(734) 663-4233
Clint Satterthwaite
(202) 374-9727
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 13.01.2012 - 08:30 Uhr
Sprache: Deutsch
News-ID 1072741
Anzahl Zeichen: 0
contact information:
Contact person:
Town:
ANN ARBOR, MI
Phone:
Kategorie:
Drugs
Anmerkungen:
Diese Pressemitteilung wurde bisher 88 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Innovative Research Company Welcomes Congressman John Dingell to Its World Headquarters in Ann Arbor, Michigan
"
steht unter der journalistisch-redaktionellen Verantwortung von
TSRL, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
